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The social defeat mouse model is used as a preclinical model for major depressive disorder (MDD). This
model is of interest, as mice subjected to chronic social defeat can be separated into stress susceptible (SS)
and resilient (SR) subgroups that differ in deﬁned behavioural and physiological characteristics. Here, we
have carried out proteomic analyses of serum and brain samples from SS (n¼12), SR (n¼12) and unstressed
control (n¼12) mice, using two analytical platforms to gain insight into the underlying molecular pathways
that distinguish these subgroups. Multiplex immunoassay proﬁling was performed using sera collected after
10 days of chronic social defeat. This analysis identiﬁed peripheral alterations in proteins mostly associated
with inﬂammation in SS mice, whereas growth factors and hormones were changed predominantly in the SR
subgroup. Label free liquid chromatography mass spectrometry (LC–MSE) proﬁling of frontal cortex revealed
a signiﬁcant increase in myelin-associated proteins [2′,3′-cyclic-nucleotide 3′-phosphodiesterase (CN37),
mylein basic protein (MBP), and myelin proteolipid protein (MYPR)] in the SR group, suggesting that resi-
lience to social stress might be mediated through activation of oligodendrogenesis. Taken together, these
results provide the ﬁrst proteomic evidence of differential effects on oligodendrocyte function between
susceptible and resilient subgroups in the social defeat model and suggest that neuronal conductivity or
central nervous system maintenance in the frontal cortex are involved in the adaptive response to stress.
These changes appear to be reﬂected by serum alterations in inﬂammation and growth-related proteins,
which could be used as biomarkers for predicting or monitoring stress response.
& 2015 Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Despite the profound negative effects of major depressive dis-
order (MDD) on public health and the associated suicide risk of
15%,1 there has been little progress in our understanding of the
pathophysiological processes involved and the discovery of new
therapeutic mechanisms is at a near standstill. This is partially due
to the limited availability of preclinical models that accurately re-
ﬂect symptoms of affective disorders.2 Nevertheless, their use isn open access article under the CC
sychiatric Research, Depart-
iversity of Cambridge, Tennis
334162.
(V. Stelzhammer),
. Gottschalk),
es@mssm.edu (G.E. Hodes),
ahmoune),
@mssm.edu (S.J. Russo),currently indispensible in psychiatric research, since ethical
and practical factors restrict the ability to study MDD in human
subjects.
Since MDD is a multifaceted disorder, it is unlikely that its
entire symptom spectrum can be accurately recapitulated in a
single preclinical model. Due to constraints in their face validity
only certain affective symptom dimensions can be modelled, such
as anhedonia or behavioural despair.2 Most preclinical models
used in MDD research have been investigated because they show
behavioural endophenotypes similar to human MDD patients.
However, there have been relatively few studies which have in-
vestigated the underlying proteomic pathophysiology in these
models. So far, studies in preclinical chronic mild stress models
were limited to the use of two-dimensional gel electrophoresis
reporting abundance changes involved in energy and protein
metabolism.3–5 Further research applying advanced proteomic
techniques is important to identify reproducible molecular chan-
ges which can be translated to patient studies.BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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MDD [reviewed in Ref. 6]. Emerging evidence suggests that a
combination of genetic and lifetime stress factors may ultimately
determine the vulnerability of individuals to develop psychiatric
disorders such as MDD [reviewed in Ref. 7]. One preclinical model
of MDD, based on naturalistic stressors, is the social defeat (SD)
model. In this paradigm, an intruder mouse is exposed repeatedly
to an aggressive and dominant resident and to bouts of social
subordination. The defeated animal may be returned to the ag-
gressor's cage for repeated social defeats or placed in close
proximity to the aggressor or in the vacant cage of the aggressor to
reinforce the negative experience [reviewed in Ref. 6]. After these
chronic defeats, stress susceptible (SS) mice show a range of de-
pression-like symptoms including anhedonia and social
withdrawal.8 These symptoms have been shown to be reversible
by chronic but not acute antidepressant drugs (ADs),8 demon-
strating the face and predictive validity of the SD paradigm. An-
other advantage of the SD model is that it can be used to study
factors involved in the resilience to SD stress. This is because a
subset of animals of this model does not develop social avoidance
behaviour. Investigations focussing on these stress resilient (SR)
animals may help to elucidate why in some individuals exposure
to chronic stress leads to an imbalance in physiological and be-
havioural homoeostasis9 which can result in MDD, while the
majority of individuals appear to be resilient against such
imbalances.7,10
In this study, we have focused on the identiﬁcation of central
nervous system (CNS) molecular changes in the SD mouse model
subgroups, SS and SR, compared to control mice. In addition,
peripheral effects were investigated, as such changes can be
translated more readily to clinical studies. Therefore, blood serum
and brain samples from these mice were analysed using multiplex
immunoassay and liquid-chromatography mass spectrometry (LC–
MSE) approaches, respectively. Our goal was to identify a transla-
tional molecular signature to evaluate the potential and relevance
of this model in MDD research and in drug discovery.Table 1
Multiplex immunoassay proﬁling results of serum from social defeat susceptible (SS, n¼
changed proteins along with their fold changes (FC). FC values are calculated based on ave
post-hoc test for Kruskal–Wallis one-way analysis of variance (ANOVA) (po0.05)] and
po0.05 is shown in Supplementary Table 2.
Protein Stress susceptible (SS)
FC p-value
Myeloperoxidase 2.60 0.0006
Matrix metalloproteinase-9 2.38 0.0016
Monocyte chemotactic protein 3 2.06 0.0005
C–C motif chemokine 9 1.66 0.0006
Interleukin-1 beta 1.52 0.0047
Clusterin 1.45 0.0003
C-reactive protein 1.37 0.0056
Adrenocorticotrophic hormone 1.37 0.0019
Angiotensin-converting enzyme 1.32 0.0045
Interleukin-1 alpha 1.22 0.0398
Epidermal growth factor 2.50 0.7717
Vascular endothelial growth factor A 1.26 0.0026
Tumour necrosis factor-α 1.65 0.3486
Macrophage migration inhibitory protein 2 2.37 0.0045
Interferon-γ 1.15 0.8024
Macrophage colony-stimulating Factor 1 1.04 0.7290
Insulin 1.15 0.1324
Macrophage-derived chemokine 1.11 0.1186
Progesterone 1.36 0.0303
Immunoglobulin A 1.03 0.84282. Results
2.1. Serum analysis (multiplex immunoassay)
Systemic responses to stress in the SS and SR mice were mea-
sured by analysing 89 immune system and metabolic circulating
markers in serum. The full list of molecules investigated is listed in
Supplementary Table 1. Inspection of intensity data by principal
component analysis (PCS) of all molecules tested with the multiplex
immunoassay panels revealed no outliers and no batch effects in-
dicating good sample and data quality. Therefore, data from all
samples were used in the statistical analyses. This resulted in iden-
tiﬁcation of 10 and 13 signiﬁcant molecular changes in sera from SS
and SR mice, respectively (Table 1). Three of these molecules, in-
cluding angiotensin-converting enzyme (ACE), interleukin 1 alpha
(IL-1α), and matrix metalloproteinase-9 (MMP9), were altered in
both subgroups, with the same direction of change and all are in-
volved in the inﬂammation response.
In the SS group, myeloperoxidase (MPO), MMP-9 and MCP-3
were all changed by more than 2-fold compared to control un-
stressed mice. These proteins have all been perviously associated
with the inﬂammation response. The remaining proteins which
were altered in the SS mice are involved in inﬂammation (C–C
motif chemokine 9, IL-1β, clusterin and C-reactive protein) or
stress response [adrenocorticotrophic hormone (ACTH)].
In the SR group, epidermal growth factor (EGF), vascular en-
dothelial growth factor A (VEGFA), tumour necrosis factor alpha
(TNF-α) and immunoglobulin A (IgA) showed the highest magni-
tude of change, as these proteins were altered by more than 2-fold.
The ﬁrst two of these proteins are growth factors and the latter
two are associated with the inﬂammation response. The other
proteins altered in the SR mice were either inﬂammation-related
proteins (macrophage migration inhibitory protein 2, interferon-γ,
macrophage colony-stimulating factor 1 and macrophage-derived
chemokine) or hormones (insulin and progesterone).
2.2. Brain analysis (LC–MSE proﬁling)
LC–MSE analysis was carried out on frontal cortices from the SS12) and resilient (SR, n¼12) mice versus controls. The table shows 20 signiﬁcantly
rage (stressed/control) or median (indicated with )^, p-values [Mann Whitney U test,
q-values (corrected Mann Whitney U test p-value). A complete list of proteins with
Stress resilient (SR)
q-value FC p-value q-value
0.0140 1.46 0.0102 0.4733
0.0130 1.21 0.0208 0.0353
0.0204 1.01 0.7289 1.0000
0.0058 1.12 0.1408 0.3441
0.0018 1.30 0.1578 0.4223
0.0009 1.12 0.5825 0.1584
0.0009 1.04 0.6297 1.0000
0.0140 1.14 0.1147 0.1050
0.0029 1.56 0.0018 0.0003
0.0135 1.64 0.0099 0.0055
0.0078 3.50 0.0054 0.0018
1.0000 3.14^ 0.0006 0.0162
1.0000 2.70 0.0082 0.0352
1.0000 1.72 0.0032 0.0357
0.3566 1.64^ 0.0176 0.0199
0.0135 1.29 0.0056 0.0097
1.0000 1.24 0.0178 0.0049
0.0059 1.41 0.0005 0.0453
0.2356 1.99 0.0002 0.0212
0.0494 2.36 0.0016 0.0004
Table 2
Signiﬁcant protein changes in frontal cortex from social defeat model subgroups, social susceptible (SS) and social resilient (SR) animals, by LC–MSE. The table shows the 10
most signiﬁcant proteomic changes (qo0.05, and FC410%) in SS animals (n¼11) and SR animals (n¼11) versus controls. The full list can be viewed in Supplementary
Table 2. The changes are sorted 1st by group and 2nd by highest to lowest fold change. The table includes short name (Code) and description of protein, peptide count (Pep),
fold change (FC) which are calculated based on average (stressed/control), p-values (Mann Whitney U test, post-hoc test for Kruskal–Wallis one-way ANOVA (po0.05)) and
q-values (false discovery rate (FDR) correction of MannWhitney U test). Signiﬁcant p-values are highlighted in bold and proteins indicated with '-' were detected in the study
but had a p-value 40.1. p-values are not shown for these proteins for better clarity of the table. A complete list of proteins with po0.05 is shown in Supplementary Table 3.
Code Protein name Pep Stress susceptible (SS) Stress resilient (SR)
FC p-value q-value FC p-value q-value
PSA Puromycin sensitive aminopeptidase 3 1.14 0.0557 1.0000 1.69 0.0008 0.0356
IC1 Plasma protease C1 inhibitor 2 1.12 0.1164 1.0000 1.52 0.0002 0.0334
MYPR Myelin proteolipid protein 24 1.05 0.4779 0.0250 1.47 0.0004 0.0335
MBP Myelin basic protein 33 1.01 1.0000 0.8109 1.42 0.0004 0.0335
CN37 2 3 cyclic nucleotide 3 phosphodiesterase 51 1.05 0.2169 1.0000 1.40 0.0003 0.0335
MK01 Mitogen activated protein kinase 1 23 1.07 0.0759 0.0577 1.11 0.0014 0.0438
SV2B Synaptic vesicle glycoprotein 2B 9 1.04 0.2169 1.0000 1.14 0.0008 0.0354
TBA1B Tubulin alpha 1B chain 12 1.03 0.2703 0.0199 1.14 0.0008 0.0354
NEUM Neuromodulin 20 1.07 0.1513 1.0000 1.17 0.0010 0.0374
LPHN2 Latrophilin-2 2 1.29 0.1014 1.0000 1.45 0.0006 0.0335
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(n¼12) mice. The CV of the QC samples was 17.79714.36 (average
7 standard deviation). Overall, 12,127 peptides were detected in
the frontal cortex which corresponded to 975 unique proteins.
Supplementary Table 3 shows the full list of altered proteins in
frontal cortex (qo0.1).
No proteins were identiﬁed with signiﬁcantly different abun-
dance between the SS and control mice at a strict q-value of
o0.05 (Table 2). In contrast, 10 signiﬁcantly changed proteins
were identiﬁed in frontal cortices from SR compared to control
mice. These proteins were involved in blood clotting (plasma
protease C1 inhibitor), synaptic vesicle release (tubulin alpha 1B
chain, mitogen activated protein kinase 1 and latrophilin-2), cell
growth [neuromodulin and puromycin sensitive aminopeptidase
(PSA)) and in myelin-associated processes (2′,3′-cyclic-nucleotide
3′-phosphodiesterase (CN37), myelin basic protein (MBP), myelin
proteolipid protein (MYPR)].
PSA showed the most marked difference with a fold change of
1.69. Additionally, ﬁve proteins (plasma protease C1 inhibitor, la-
trophilin, CN37, MBP, MYPR) were altered by more than 1.4-fold.3. Discussion
This is the ﬁrst study which investigated molecular proﬁling
differences in serum and brain of the SD model to take into account
differences between SS and SR mice. This allowed the detection of
different molecular signatures between the two subgroups. The
serum analysis showed several differences in the proteins altered in
the two groups. Proteins mostly associated with the inﬂammatory
response were altered in the SS mice and proteins associated with
cell growth/proliferation were changed in both the SS and SR mice,
whereas growth factors and hormones were changed pre-
dominantly in the SR animals. This suggests that SS mice showed
signs of undergoing an enhanced inﬂammatory response.
Several studies have put the notion forward that inﬂammatory
mechanisms play an important role in MDD, with ﬁndings of ele-
vated levels of pro-inﬂammatory cytokines and other inﬂammation-
related proteins in blood, cerebrospinal ﬂuid (CSF) and post-mortem
brain tissue of MDD patients [reviewed in Ref. 11]. Furthermore, it
has been hypothesised that immunological disorders and MDD may
share a common pathophysiological process linked to immune
dysregulation.12 This is consistent with our ﬁndings since both SD
subgroups showed elevated levels of pro-inﬂammatory or stress-re-
lated proteins, such MMP9, ACE and IL-1-α. However, the SS groupshowed speciﬁc increases in additional inﬂammation proteins (e.g.
MPO, monocyte chemotactic protein 3, C–C motif chemokine 9, IL-
1β, clusterin, C-reactive protein and ACTH), and such proteins have
been shown to be also elevated in MDD patients.13-18 The ﬁnding
that the SS mice also displayed increased levels of ACTH was in-
dicative of activation of the hypothalamic-pituitary-adrenal(HPA)-
axis in these animals. Previous studies have shown that the release of
ACTH is stimulated by pro-inﬂammatory cytokines [reviewed in Ref.
19], which is consistent with the pro-inﬂammatory ﬁndings in the SS
model discussed above. As increased ACTH levels have been pre-
viously reported in MDD patients,20,21 these ﬁndings support the use
of the SS rodents as a putative MDD animal model with associated
hyperfunction of the HPA-axis. Previous studies have suggested that
increased ACTH secretion occurs in depressed in-patients regardless
of the cortisol-emic state and that ACTH-independent hypercortiso-
lemia mainly results from physiological stress in severe cases of
MDD.22 Interestingly, the SR mice showed speciﬁc changes in growth
factors and hormones in addition to Inﬂammation-related changes.
This could be an adaptive response to stress, which may require
tissue repair. For example, insulin was elevated in sera from the SR
mice and this hormone is known to have profound effects on neu-
ronal functions as it modulates neurotransmitter channel activity,
brain cholesterol synthesis and mitochondrial function, and the dis-
ruption of brain insulin signalling leads to impaired neuronal func-
tion and synaptogenesis.24 However, the ﬁnding that progesterone
was markedly lower (1.99 fold) in SR mice appears to be contra-
dictory, as this hormone is also involved in synaptic growth25 but has
also been linked to social rejection and subsequent coping strategies
and changes in GABAergic neurotransmission in humans and
rodents.26 The SR group showed increased levels of different in-
ﬂammatory proteins, such as interferon-γ, which has also been re-
ported previously in clinical MDD studies.27,28 It have shown that this
protein may have an inhibitory effect on cell growth and
proliferation.29–32 However, previous studies have found decreased
neuronal cell proliferation in the SD model during and immediately
after stress [reviewed in Refs. 33,34]. Furthermore, other studies have
reported impaired cell proliferation mechanisms in brains from SD
animals.8,35 One investigation found decreased hippocampal neuro-
genesis in SS and SR animals immediately after the last stress epi-
sode, by measuring subgranular zone (SGZ) cells in the dentate gyrus
labelled with the S-phase marker bromodeoxyuridine (BrdU).35
Previous studies have shown that peripheral growth factors,
such as basic epidermal growth factor, and treatments affecting
peripheral cytokines can induce adult brain neurogenesis and
neuroprotection, as these molecules can cross the blood brain
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Therefore, increases in cell proliferation markers seen 48 h
after stress in our study could be associated with the early phase of
enhanced compensatory cell proliferation seen 4 weeks after the
last defeat in SS animals by Legace et al.35 Taken together, our data
suggest that the effects on serum molecules in the SS and SR an-
imals may reﬂect changes in neuronal compensation for trauma-
induced plasticity following SD stress. It should be noted however,
that the majority of proteins assessed by the multiplex im-
munoassay are involved in inﬂammatory and immune-related
functions. Nevertheless, despite this fact the SS and SR mice
showed different proﬁles in proteins associated with this mole-
cular function, underlining the methodical need to detect a diverse
range of proteins in already implicated common disease pathways
in the peripheral pathophysiology of depression. One of the trade-
offs of high throughput screening techniques (the same is true for
the LCMSE approach) is the requirement for strict correction for
multiple hypothesis testing. This could mask the detection of some
effects of SD (e.g. reductions in serum testosterone or corticos-
terone) to be detected as not signiﬁcant in the current pilot study
(compare Supplementary Table 2, uncorrected p-value for corti-
costerone in the SD group: 0.0627; FC 1.37).
Interestingly, the LCMSE proﬁling analysis identiﬁed no changes
in the frontal cortex from the SS mice. This could reﬂect the pos-
sibility that these mice showed few or no fronto-cortical adaptive
changes to stress, or that the SD protocol resulted in macroscopic
structural changes that could not be detected using our proteomics
approach. In contrast, 10 proteins were found to be altered in frontal
cortex tissue from the SR mice following relative quantiﬁcation and
these were mostly involved in synaptic or myelin-related functions.
This suggests that animals failing to up-regulate such proteins may
suffer negative effects associated with SD or that animals with in-
creased synaptic and myelin density prior to the defeat procedure
are more stress resistant. MBP and CN37 are markers of mature
oligodendrocytes.38 These specialised cells are an important part of
the CNS maintenance of axonal integrity39,40 and signal
transduction.41 Frontal cortex upregulation of oligodendrogenesis
has previously been linked to processes that ameliorate depression-
related behaviour. Chronic unpredictable stress has been shown to
decrease fronto-cortical proliferation of oligodendrocytes and to be
reversible by antidepressant treatment.42 Additionally, electro-
convulsive seizure treatment in rodents has been demonstrated to
increase hippocampal43 and frontal cortex44 gliogenesis. On the
other hand, chronic stress hormone exposure leads to a decrease in
cortical oligodendrocyte proliferation.45 This is noteworthy since
ACTH was only found to be signiﬁcantly increased in the susceptible
animals in our study, suggesting that only this group shows HPA-
axis activation and subsequently develops abnormal behaviour. In-
creased myelination as a marker of resilience against stressors could
represent an interesting translational ﬁnding. The overall frontal
cortex oligodendrocyte density in post-mortem brain of depressive
patients has been found to be decreased,46 although targeted pro-
teomic studies suggested no expression changes47 of oligoden-
drocyte-related proteins. Future preclinical studies should in-
vestigate the time course of myelin-related pathologies following
stress exposure and the possibility to rescue depressive phenotypes
by pharmacological myelin enhancement.
Previous studies have shown that neurons of the frontal cortex
are sensitive to stress and undergo remodelling following stress
exposure [reviewed in Ref. 48] which may further support our re-
sults. Additionally, the frontal cortex plays a major role in orches-
trating the behavioural and systemic responses to stress and is in-
volved in working memory, decision making, social interactions and
emotional processing [reviewed in Ref. 49], which overlap with the
current molecular ﬁndings. Our results suggest the intriguing pos-
sibility that resilience in this model is associated with increasedoligodendrogenesis in the frontal cortex. Recently it has been
shown that stress hormones increase oligodendrogenesis in the
hippocampus, a limbic brain region important for memory and
emotional control.50 Since neuronal and synaptic remodelling as
well as the strength of synaptic transmission has been associated
with memory and learning [reviewed in Refs. 51,52] and the frontal
cortex has inhibitory control over the limbic system, the present
ﬁndings suggest that the SR mice cope with traumata-induced
stress by compensating for decreased hippocampal neurogenesis
with increased fronto-cortical oligodendrogenesis. This is in line
with ﬁndings that fronto-cortical integrity and increased frontal
neuronal activity are mediators of antidepressant-like effects in SD
mice.53 In concordance with this hypothesis Bartzokis has already
suggested myelin as a central point of convergence of multiple
psychotropic treatments including antidepressants.54 Alterations in
network synchronicity and overall transmission speed have been
suggested as the underlying pathophysiology.55,56 Interestingly, the
frontal cortex is a particularly vulnerable brain region, as it is one of
the late-myelinating areas.57
This is the ﬁrst molecular proﬁling study which investigated
differences in serum and frontal cortex of the SD mouse model.
Serum analysis showed alterations predominantly in inﬂammatory
proteins in both SS and SR mice, whereas growth factors and hor-
mones were also altered in SR animals. The latter ﬁnding was
particularly interesting as these could be linked to different beha-
vioural responses to stress. Frontal cortex proteomics analysis, using
LC–MSE proﬁling, provided evidence of differential molecular
adaptations in brain tissue, particularly affecting synaptic and
myelin-related proteins. This may provide novel insights into how
resilient mice can avert the negative consequences of social stress,
although future work has to examine whether central myelin-re-
lated or peripheral inﬂammation-related changes are induced by
acute stress exposure or are already established prior to the SD
procedure. Taken together, these central and peripheral ﬁndings
suggest that further studies investigating the distinct susceptibility
and resilience responses in the SD model of depression may aid in
the search of novel antidepressant drug targets. An experimental
agent stabilizing Axin258 and natural cannabinoids59 have already
been shown to enhance myelination by inﬂuencing oligodendrocyte
differentiation and maturation, opening novel therapeutic possibi-
lities that could be explored to improve the treatment of MDD.4. Materials and methods
4.1. Animals, housing conditions and stress treatment
Male 7–9 week old C57BL/6J mice (Jackson Laboratory; Bar
Harbor, ME, USA) and male 9–13 month old CD-1 retired breeder
mice (Charles River Laboratories; Wilmington, MA, USA) were
housed under constant temperature (2171 °C), humidity (50–58%)
and a 12 h light/dark cycle with free access to food and water. An-
imals were allowed to acclimatise to the facility for 1 week before
experimentation. C57BL/6J mice were subjected to chronic SD stress
as described previously by Berton et al., Krishnan et al., and Golden
et al.8,60,61 In short, CD-1 mice were screened for aggressive beha-
viour triggered by intrusion into their home cages. Mice exhibiting
this trait were used in the SD model as the aggressor mouse to
defeat the C57BL/6J mice. The C57BL/6J mice were placed in the
home cages of CD-1 mice and subjected to a bout of SD by the
aggressor mouse for 10 minutes each day. For the remainder of the
day, C57BL/6J mice stayed in the cage with the aggressor but were
separated by perforated Plexiglas divider to allow sensory contact
but no physical interaction. This process was repeated daily for 10
consecutive days using a different CD-1 aggressor mouse each day
to minimise inter-aggressor variability. Control animals were
V. Stelzhammer et al. / Diagnostics in Neuropsychiatry 1 (2015) 1–7 5housed in divided cages with another C57BL/6J mouse.
On day 11, the mice exposed to SD stress were subjected to a social
interaction test as described by Krishnan et al. and Golden et al.8,61
Brieﬂy, a video-tracking system was used to score interaction/avoid-
ance behaviours towards an unfamiliar ‘social target’ (male CD-1
mouse). Video recordings were performed using a camera equipped
with infra-red ﬁlter and lights. A white plastic open ﬁeld (4242 cm)
maintained under red light was used as the arena for the social in-
teraction test. Each experimental C57BL/6J mouse was introduced into
the open ﬁeld and its trajectory tracked for two consecutive sessions
of 2.5 min. Between sessions, the mice were placed into their home
cages for approximately 1 min. For the ﬁrst session (‘no-target’ ses-
sion), the mice were put into the open ﬁeld containing an empty wire
mesh cage (106.5 cm) located at one end. For the second session
(‘target’ session), the mice were put into the open ﬁeld under the
same conditions except that an unfamiliar male CD-1 mouse was
present in the wire mesh cage. Video-tracking data from both ses-
sions were used to determine the time spent by the C57BL/6J mouse
in the ‘interaction zone’ (8 cm wide area surrounding the wire mesh
cage) and the ‘corners’ of the open ﬁeld, opposite to the location of
the wire mesh cage that was used to calculate the social interaction
ratio. Typical social interaction test behaviour of defeated C57BL/6J
animals and control animals can be found references 8 and 60.
Based on interaction score ratios of this test, the C57BL/6J mice
were sorted into either susceptible (SS) (n¼12) or resilient (SR)
(n¼12) groups (the latter showed social interaction behaviour si-
milar to controls; n¼12). A ratio equal to 1, in which equal time of
the C57BL/6J mouse is spent in the presence and absence of a CD-1
mouse in the interaction zone, has been used as a threshold for
dividing defeated mice into the two subgroups (o1: susceptible;
41: resilient). Finally, 48 h after the last defeat and 24 h after social
interaction testing, all SS, SR and non-stressed control animals were
decapitated and serum (trunk blood) and brain (frontal cortex)
samples were taken. Samples were stored at 80 °C.
4.2. Multiplex immunoassay serum proﬁling
A total of 89 molecules were measured in serum samples
(200 mL) using the multiplexed immunoassay RodentMAPss plat-
form in the Clinical Laboratory Improvement Amendments-certi-
ﬁed laboratory at Myriad-RBM (Austin, TX, USA). The Ro-
dentMAPss platform consisted of RodentMAPs–2.0, Rat Metabolic
MAPs–v1.0 and Rat KidneyMAPs–v.1.0 panels. The method has
been previously described in detail.62 The full list of molecules
tested is shown in Supplementary Table 1.
4.3. Label free LC–MS proteomic proﬁling
4.3.1. Protein extraction, fractionation and digestion
All biochemical reagents were purchased from Sigma-Aldrich,
Dorset, UK, unless speciﬁed otherwise. We used a label free LC–MSE
approach to proﬁle proteins extracted from brain tissue as de-
scribed previously.63 Brieﬂy, proteins were extracted from frontal
cortex (25–70 mg) by adding 5 volumes of extraction buffer/tissue
weight. The extraction buffer consisted of 7M urea, 2M thiourea, 4%
3-[(3-cholamidopropyl) dimethylammonio]-1-propanesulfonate
(CHAPS), 2% 3-[N,N-dimethyl (3-myristoylaminopropyl) ammonio]
propanesulfonate amidosulfobetaine-14 (ASB14, Calbiochem;
Beeston, UK) and 70 mM dithiothreitol. The samples were sonicated
using a Branson Soniﬁers W-150 (York, UK) for an initial 10 s and
for another 5 s at 4 °C. In parallel to the animal model samples,
quality control (QC) samples were prepared from spare mouse
frontal corteces. After fractionation of all the QC samples, the QCs
were pooled and aliquoted. A QC sample was added to each sample
preparation batch and prepared as it would be a normal sample.
After sonication, the samples were put on a Vortex-genies2 shaker(VWR International; Radnor, PA, USA) at level 2 and 4 °C for 30min
and then centrifuged at 17,000g for 3 min at 4 °C, using a Spectrafuge™
24D Digital microcentrifuge (Labnet International; Windsor, UK). After
protein concentration measurement (Bradford reagent), 1000 mg of
frontal cortex proteins were precipitated using 4 volume equivalents of
20 °C cold acetone and incubated at 20 °C for 16 h. The samples
were centrifuged at 13,000 rpm for 10min at 4 °C. The acetone was
discarded and the pellets were resuspended in 100 mL of 50mM am-
monium bicarbonate. Disulphide bonds were reduced using 100mM
dithiothreitol at 60 °C for 30min and free sulfhydryl groups were al-
kylated with 200mM iodoacetamide in the dark at room temperature
for 30 min. The proteins were digested using trypsin (Promega; Ma-
dison, WI, USA), at a ratio of 1:50 (w/w trypsin/protein) for 17 h at
37 °C. Digestions were stopped by addition of 8.8 M HCl (ratio¼1:60)
to each sample and the samples were stored at 80 °C.
4.3.2. Liquid chromatography and mass spectrometry analysis
The LC–MSE proﬁling study was carried out in expression mode
using a Waters quadrupole time-of-ﬂight (QToF)-PremierTM (Waters
Corporation; Milford, MA, USA) mass spectrometer, as described
previously.64 Adaptations to the protocol were made as described
below. The LC–MSE analysis was carried out in duplicate for all
samples, using 0.6 mL of protein digest for 5 mL of sample. The buffers
used were: (A) H2Oþ0.1% formic acid and (B) acetonitrileþ0.1%
formic acid. Desalting of the samples was performed online with
100% A for 2 min, using a reverse-phase C18 trapping column
(180 mm inner diameter (i.d.) 20 mm length, 5 mm particle size)
(Waters). Peptides were separated using an analytical C18 BEH nano-
column (75 mm i.d., 200 mm length, 1.7 mm particle size) (Waters) at
0.3 mL/min, using a 131 min gradient. The gradient started with an
initial concentration of 3% B (97% A), followed by 3–30% B (90 min),
30–90% B (25 min), 90–97% B (5 min), constant 97% B (10 min), and
97–3% B (1 min).
The resulting data were processed using the ProteinLynx Global
Server (PLGS) v.2.4 (Waters) and Rosetta Inpharmatics Biosoftware
Elucidator v3.3 (Seattle, WA, USA).65 A mouse Swiss-Prot database
(version 57.4, 16 140 entries) search analysis was performed using
PLGS with the ion accounting algorithm described previously.66 The
criteria for protein identiﬁcation were set to Z3 fragment ions/pep-
tide, and Z7 fragment ions and 2 peptides/protein. The maximum
false identiﬁcation rate was 4% using a randomized version of the
database. Only peptides detected in both replicates and in 60% of all
the samples were included in the further analysis. Search results were
imported into Elucidator for annotation of aligned features, resulting in
a matrix that included intensities for each sample and peptide. Only
proteins represented by 2 or more peptides were included in the ﬁnal
result lists. Note that the PLGS search algorithm and the subsequent
data integration does not speciﬁcally distinguish between splice var-
iants of proteins. Only the most commonly accepted “canonical” splice
variant is usually integrated in the Swiss-Prot database and peptides
that are not unique for a given protein or group of isoforms are re-
moved from the analysis process in order to remove redundancy.
4.3.3. Statistical analyses
The quality of recorded multiplex immunoassay and LC–MSE data
was assessed by PCS using Prism version 5 (GraphPad Software, La
Jolla, CA, USA). The PCA is particularly suited for the visual display of
multi-dimensional data as the dataset is projected to few (mostly two)
dimensions that account for the greatest variance (information) in the
dataset, and thereby can be used to identify possible outliers or batch
effects. For multiplex immunoassay analyses, values under the detec-
tion limit were replaced as described previously.67 Furthermore, mo-
lecules which had more than 20% of values outside the detection limit
within a group were not included in the ﬁnal list of changedmolecules
or otherwise indicated. For all LC–MSE studies, coefﬁcients of variation
(CVs) were calculated using the QC measured intensities. The overall
V. Stelzhammer et al. / Diagnostics in Neuropsychiatry 1 (2015) 1–76study CV was calculated as the mean of total protein CVs to assess the
technical variation.
The non-parametric Kruskal–Wallis one way ANOVA with
Mann Whitney U test as post-hoc test were applied for statistical
analyses of the multiplex immunoassay and LC–MSE data. FDR was
used to control for multiple hypothesis testing (q-value) and a q-
value of each molecule was calculated according to the method of
Benjamini and Hochberg.68 All analyses were performed using the
statistical software package R 2.12.69 All ratios which had a Krus-
kal–Wallis one way ANOVA qo 0.05 and Mann Whitney U qo
0.05 (for at least one comparison) were considered as signiﬁcantly
different.
FCs were calculated for each molecule as the mean value
of the stressed animals divided by mean value of controls (SS/C
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